Alcohol dose in septal ablation for hypertrophic obstructive
cardiomyopathy

J 2021

Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy

VESELKA, Josef, Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA et. al.

Základní údaje

Originální název

Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy

Autoři

VESELKA, Josef (203 Česká republika, garant), Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA (203 Česká republika), Maksim KASHTANOV, Maciej DABROWSKI, Peter Riis HANSEN, Hubert SEGGEWISS, Jiri BONAVENTURA (203 Česká republika), Eva POLAKOVA (203 Česká republika), Eva HANSVENCLOVA (203 Česká republika), Henning BUNDGAARD, Jurrien TEN BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ (203 Česká republika, domácí) a Morten Kvistholm JENSEN

Vydání

International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2021, 0167-5273

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.039

Kód RIV

RIV/00216224:14110/21:00123837

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.ijcard.2021.02.056

UT WoS

000730511500028

Klíčová slova anglicky

Alcohol septal ablation; Hypertrophic cardiomyopathy; Alcohol dose

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 7. 2023 12:58, Mgr. Tereza Miškechová

Anotace

V originále

Background: The aim of this study was to evaluate short-and long-term outcomes related to dose of alcohol administered during alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM). Current guidelines recommend using 1-3 mL of alcohol administered in the target septal perforator artery, but this recommendation is based more on practical experience of interventionalists rather than on systematic evidence. Methods: We included 1448 patients and used propensity score to match patients who received a low-dose (1.0-1.9 mL) versus a high-dose (2.0-3.8 mL) of alcohol during ASA. Results: The matched cohort analysis comprised 770 patients (n = 385 in both groups). There was a similar occurrence of 30-day post-procedural adverse events (13% vs. 12%; p = 0.59), and similar all-cause mortality rates (0.8% vs. 0.5%; p = 1) in the low-dose group and the high-dose group, respectively. In the long-term follow-up (5.4 +/- 4.5 years), a total of 110 (14%) patients died representing 2.58 deaths and 2.64 deaths per 100 patient years in the low dose and the high dose group (logrank, p = 0.92), respectively. There were no significant differences in the long-term dyspnea and left ventricular outflow gradient between the two groups. Patients treated with a low-dose of alcohol underwent more subsequent septal reduction procedures (logrank, p = 0.04). Conclusions: Matched HOCM patients undergoing ASA with a low-dose (1.0-1.9 mL) or a high-dose (2.0-3.8 mL) of alcohol had similar short-and long-term outcomes. A higher rate of repeated septal reduction procedures was observed in the group treated with a low-dose of alcohol.

Citovat

VESELKA, Josef, Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA, Maksim KASHTANOV, Maciej DABROWSKI, Peter Riis HANSEN, Hubert SEGGEWISS, Jiri BONAVENTURA, Eva POLAKOVA, Eva HANSVENCLOVA, Henning BUNDGAARD, Jurrien TEN BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ a Morten Kvistholm JENSEN. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. International Journal of Cardiology. Clare: Elsevier Ireland Ltd., 2021, roč. 333, June 2021, s. 127-132. ISSN 0167-5273. Dostupné z: https://dx.doi.org/10.1016/j.ijcard.2021.02.056.

@article{1823829,
   author = {Veselka, Josef and Faber, Lothar and Liebregts, Max and Cooper, Robert and Januska, Jaroslav and Kashtanov, Maksim and Dabrowski, Maciej and Hansen, Peter Riis and Seggewiss, Hubert and Bonaventura, Jiri and Polakova, Eva and Hansvenclova, Eva and Bundgaard, Henning and ten Berg, Jurrien and Stables, Rodney Hilton and Jarkovský, Jiří and Jensen, Morten Kvistholm},
   article_location = {Clare},
   article_number = {June 2021},
   doi = {http://dx.doi.org/10.1016/j.ijcard.2021.02.056},
   keywords = {Alcohol septal ablation; Hypertrophic cardiomyopathy; Alcohol dose},
   language = {eng},
   issn = {0167-5273},
   journal = {International Journal of Cardiology},
   title = {Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy},
   url = {https://www.sciencedirect.com/science/article/pii/S016752732100365X?via%3Dihub#!},
   volume = {333},
   year = {2021}
}

TY  - JOUR
ID  - 1823829
AU  - Veselka, Josef - Faber, Lothar - Liebregts, Max - Cooper, Robert - Januska, Jaroslav - Kashtanov, Maksim - Dabrowski, Maciej - Hansen, Peter Riis - Seggewiss, Hubert - Bonaventura, Jiri - Polakova, Eva - Hansvenclova, Eva - Bundgaard, Henning - ten Berg, Jurrien - Stables, Rodney Hilton - Jarkovský, Jiří - Jensen, Morten Kvistholm
PY  - 2021
TI  - Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy
JF  - International Journal of Cardiology
VL  - 333
IS  - June 2021
SP  - 127-132
EP  - 127-132
PB  - Elsevier Ireland Ltd.
SN  - 01675273
KW  - Alcohol septal ablation
KW  - Hypertrophic cardiomyopathy
KW  - Alcohol dose
UR  - https://www.sciencedirect.com/science/article/pii/S016752732100365X?via%3Dihub#!
N2  - Background: The aim of this study was to evaluate short-and long-term outcomes related to dose of alcohol administered during alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM). Current guidelines recommend using 1-3 mL of alcohol administered in the target septal perforator artery, but this recommendation is based more on practical experience of interventionalists rather than on systematic evidence. Methods: We included 1448 patients and used propensity score to match patients who received a low-dose (1.0-1.9 mL) versus a high-dose (2.0-3.8 mL) of alcohol during ASA. Results: The matched cohort analysis comprised 770 patients (n = 385 in both groups). There was a similar occurrence of 30-day post-procedural adverse events (13% vs. 12%; p = 0.59), and similar all-cause mortality rates (0.8% vs. 0.5%; p = 1) in the low-dose group and the high-dose group, respectively. In the long-term follow-up (5.4 +/- 4.5 years), a total of 110 (14%) patients died representing 2.58 deaths and 2.64 deaths per 100 patient years in the low dose and the high dose group (logrank, p = 0.92), respectively. There were no significant differences in the long-term dyspnea and left ventricular outflow gradient between the two groups. Patients treated with a low-dose of alcohol underwent more subsequent septal reduction procedures (logrank, p = 0.04). Conclusions: Matched HOCM patients undergoing ASA with a low-dose (1.0-1.9 mL) or a high-dose (2.0-3.8 mL) of alcohol had similar short-and long-term outcomes. A higher rate of repeated septal reduction procedures was observed in the group treated with a low-dose of alcohol.
ER  -

VESELKA, Josef, Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA, Maksim KASHTANOV, Maciej DABROWSKI, Peter Riis HANSEN, Hubert SEGGEWISS, Jiri BONAVENTURA, Eva POLAKOVA, Eva HANSVENCLOVA, Henning BUNDGAARD, Jurrien TEN BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ a Morten Kvistholm JENSEN. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. \textit{International Journal of Cardiology}. Clare: Elsevier Ireland Ltd., 2021, roč.~333, June 2021, s.~127-132. ISSN~0167-5273. Dostupné z: https://dx.doi.org/10.1016/j.ijcard.2021.02.056.

Podrobný výpis o publikaci